A comparison of the in vitro cytotoxicity of daunorubicin and liposomal daunorubicin in pediatric acute leukemia

被引：0
|
作者：
Goemans, Bianca F. [1 ]
Zwaan, Christian M. [2 ]
Reinhardt, Dirk [3 ]
Gibson, Brenda E. S. [4 ]
Hahlen, K. [2 ,5 ]
Kaspers, Gert Jan L. [1 ,5 ]
机构：
[1] Vrije Univ Amsterdam Med Ctr, Dept Pediat Oncol Hematol, NL-1081 HV Amsterdam, Netherlands
[2] Erasmus MC Sophia Childrens Hosp, Dept Pediat Hematol Oncol, Rotterdam, Netherlands
[3] AML BFM Study Grp, Hannover, Germany
[4] UK Childhood Leukaemia Working Party, London, England
[5] Dutch Childhood Oncol Grp, The Hague, Netherlands
来源：
HAEMATOLOGICA | 2006年 / 91卷 / 11期
关键词：
liposomal daunorubicin; pediatric acute leukemia; drug sensitivity; cardiotoxicity;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Anthracyclines are effective in the treatment of leukemia, but their use is limited because of cardiotoxicity. Liposomal daunorubicin (L-DNR) is potentially less cardiotoxic than daunorubicin (DNR). We compared in vitro cytotoxicity in pediatric acute leukemia samples and found no significant differences between cytotoxicity of DNR and L-DNR.
引用
收藏
页码：1573 / 1574
页数：2
相关论文
共 50 条
  • [21] Anthracycline efficacy in vitro: Cytotoxicity of liposomal/nonliposomal daunorubicin and doxorubicin for multiple tumor cell types
    Wiles, ME
    Bell, C
    Landfair, D
    Lynam, E
    Bendele, RA
    DRUG DELIVERY, 1997, 4 (04) : 255 - 262
  • [22] DAUNORUBICIN IN THERAPY OF ACUTE GRANULOCYTIC LEUKEMIA
    WEIL, M
    GLIDEWELL, OJ
    JACQUILLAT, C
    LEVY, R
    SERPICK, AA
    WIERNIK, PH
    CUTTNER, J
    HOOGSTRATEN, B
    WASSERMAN, L
    ELLISON, RR
    GAILANI, S
    BRUNNER, K
    SILVER, RT
    REGE, VB
    COOPER, MR
    LOWENSTEIN, L
    NISSEN, NI
    HAURANI, F
    BLOM, J
    BOIRON, M
    BERNARD, J
    HOLLAND, JF
    CANCER RESEARCH, 1973, 33 (05) : 921 - 928
  • [23] Daunorubicin for the treatment of acute myeloid leukemia
    Bertuzzi, Clara
    Paolini, Stefania
    Visani, Giuseppe
    Piccaluga, Pier Paolo
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (10): : 1075 - 1087
  • [24] DAUNORUBICIN METABOLISM IN ACUTE NONLYMPHOCYTIC LEUKEMIA
    HUFFMAN, DH
    BENJAMIN, RS
    BACHUR, NR
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1972, 13 (06) : 895 - &
  • [25] DAUNORUBICIN OR DOXORUBICIN IN ACUTE MYELOGENOUS LEUKEMIA
    GALE, RP
    FOON, KA
    LEUKEMIA, 1988, 2 (04) : 209 - 210
  • [26] DAUNORUBICIN METABOLISM IN ACUTE MYELOCYTIC LEUKEMIA
    HUFFMAN, DH
    BACHUR, NR
    BLOOD-THE JOURNAL OF HEMATOLOGY, 1972, 39 (05): : 637 - &
  • [27] The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia
    Styczynski, J
    Wysocki, M
    Debski, R
    Kurylak, A
    Balwierz, W
    Rokicka-Milewska, R
    Matysiak, M
    Balcerska, A
    Kowalczyk, J
    Wachowiak, J
    Sonta-Jakimczyk, D
    Chybicka, A
    ACTA BIOCHIMICA POLONICA, 2002, 49 (01) : 99 - 107
  • [28] DAUNORUBICIN IN ADULT ACUTE LYMPHATIC LEUKEMIA
    不详
    PRACTITIONER, 1972, 209 (1254) : 863 - &
  • [29] Liposomal daunorubicin (daunoxome(R)) is cytotoxic to childhood acute lymphoblastic leukemia cells.
    Baruchel, A
    Ito, C
    Robert, J
    Campana, D
    BLOOD, 1997, 90 (10) : 3633 - 3633
  • [30] A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome
    Cortes, J
    Kantarjian, H
    Albitar, M
    Thomas, D
    Faderl, S
    Koller, C
    Garcia-Manero, G
    Giles, F
    Andreeff, M
    O'Brien, S
    Keating, M
    Estey, E
    CANCER, 2003, 97 (05) : 1234 - 1241
12345